

# Expanding blood-based risk assessment offerings with LifeLabs® p-tau181

**LifeLabs® blood-based Alzheimer's disease (AD) risk assessment portfolio now includes testing for phosphorylated tau181 (p-tau181) proteins**

Phosphorylated tau181 (p-tau181), one of the biomarkers involved in the diagnosis and staging of AD, has been shown to be detectable via plasma assay as it increases over time along with disease progression.[1,2]

## Plasma testing offers an effective and minimally invasive tool for assessment of cognitive decline[2-4]

Plasma p-tau181 concentrations increase over time with AD progression.[1,2] Routine monitoring of p-tau181 levels via plasma is **ideal to support care pathways because it is less invasive, less expensive, and more practical than other methods.**

Combining plasma p-tau181 and Aβ42/40 biomarkers can **diagnose and identify patients who may experience faster cognitive decline.**[3,4] This combination can also aid in determining further diagnostic testing or intervention needs.

| Test name | Turnaround time | Volume |
|---|---|---|
| LifeLabs® Phosphorylated tau181 (p-tau181), Plasma | 10 days | 1 mL (0.5 mL minimum) plasma (EDTA lavender top) |

## For a more robust and less invasive risk assessment, incorporate LifeLabs® p-tau181 into your clinical care

Improvement of patient outcomes and care pathways drives our continued expansion of accessible AD and dementia risk assessment offerings within the LifeLabs® blood-based portfolio.

Visit **lifelabs.com/alzheimers-disease** to see how we are transforming cognitive health assessment and diagnostics or **click here** to download requisition.

### Stay Informed with LifeLabs

Click the 'Sign up' button below and join our email list to receive the latest news and updates on diagnostic testing for AD and other therapeutic areas.

**Sign up**


**References**

1. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021;17(8):1353-1364. doi:10.1002/alz.12301 2. Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267-278. doi: 10.1007/s00401-020-02195-x 3. Meyer PF, Ashton NJ, Karikari TK, et al. Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. Ann Neurol. 2022; 91(4): 548-560. doi:10.1002/ana.26308 4. Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimers Dement. 2022;18(2):283-293. doi:10.1002/alz.12395


**www.LifeLabs.com**